8-K: Eton Pharmaceuticals Announces Change in Independent Auditor, Appoints Grant Thornton LLP

Eton Pharmaceuticals, Inc. announced the dismissal of Crowe LLP as its independent registered public accounting firm and the appointment of Grant Thornton LLP, effective June 13, 2025, with no reported disagreements or adverse opinions.

Summary

• Eton Pharmaceuticals, Inc. dismissed Crowe LLP as its independent registered public accounting firm on June 13, 2025.
• The decision to dismiss Crowe LLP was approved by the Company's Audit Committee of the Board of Directors on June 13, 2025.
• Crowe LLP's report on the Company's financial statements for the fiscal year ended December 31, 2024, did not contain an adverse opinion, a disclaimer of opinion, or any qualification or modification regarding uncertainty, audit scope, or accounting principles.
• There were no disagreements with Crowe LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure from their engagement date (June 14, 2024) through the date of the 8-K filing.
• No reportable events, as defined by Regulation S-K, occurred during Crowe LLP's engagement period.
• Grant Thornton LLP was appointed as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2025, with the appointment approved by the Audit Committee on June 13, 2025.
• The Company did not consult Grant Thornton LLP regarding the application of accounting principles or potential audit opinions prior to their appointment.

Sentiment

Score: 6

Explanation: The change in independent registered public accounting firm is a routine corporate governance event. The absence of any reported disagreements or reportable events with the dismissed auditor, Crowe LLP, indicates that the change was not prompted by accounting or auditing disputes, which is a positive signal for financial reporting integrity and suggests a normal course of business.

Positives

• Crowe LLP's audit report for the fiscal year ended December 31, 2024, was unqualified, indicating no adverse opinions, disclaimers, or modifications.
• There were no disagreements with Crowe LLP on accounting principles, financial statement disclosure, or auditing scope or procedure, suggesting a smooth transition and no underlying financial reporting issues.
• No reportable events were identified during Crowe LLP's tenure, which is a positive indicator of sound financial practices.

Future Outlook

The document primarily concerns a change in the company's independent registered public accounting firm for the fiscal year ending December 31, 2025. No other forward-looking statements or guidance on business operations or financial performance are provided.

Management Comments

• The filing was signed by James R. Gruber, Chief Financial Officer and Secretary (Principal Financial Officer).

Industry Context

Changes in independent registered public accounting firms are a routine corporate governance matter for publicly traded companies. The absence of reported disagreements or reportable events with the dismissed auditor suggests the change is not due to underlying financial reporting issues, which is generally viewed favorably by the market. This aligns with standard corporate practices for periodic review of audit services and ensuring fresh perspectives or specialized expertise.

Corporate Governance

Stakeholder Impact

• Shareholders: The change ensures continued independent oversight of financial statements, which is crucial for investor confidence. The absence of disagreements with the prior auditor suggests a smooth transition without underlying financial reporting issues, maintaining transparency and trust.

Next Steps

• Grant Thornton LLP will serve as the independent registered public accounting firm for Eton Pharmaceuticals, Inc. for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Eton Pharmaceuticals, Auditor Change, Independent Accountant, Crowe LLP, Grant Thornton LLP, SEC Filing, Form 8-K, Financial Reporting, Audit Committee, Corporate Governance